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ABSTRACT 
A simple, accurate, precise method was developed for the simultaneous 
estimation of the Quinapril and HCTZ in Tablet dosage form. Chromatogram was 
run through Inertsil ODS column (250mm: 4.6mm, 5µ). Mobile phase containing 
Buffer & Acetonitrie in the ratio of (45:55) was pumped through column at a flow 
rate of 0.8ml/min. Buffer used in this method was ortho phosphoric acid 
Temperature was maintained at 30°C. Optimized wavelength for Quinapril and 
HCTZ was 210nm. Retention times of Quinapril and HCTZ were found to be 
2.17min and 3.4min. % RSD of the Quinapril and HCTZ were and found to be 0.65 
and 0.42 respectively. % Recover was Obtained as 99.91 and 100.02 for HCTZ and 
Quinapril respectively. LOD, LOQ values are obtained from regression equations of 
Quinapril and HCTZ were 0.67, 2.03 and 0.5, 1.52 respectively. Regression equation 
of HCTZ is y = 20044x + 4078, and of Quinapril is y = 317877x + 2711 Regression 
co-efficient was 0.999. 
Key Words:  HCTZ, Quinapril, RP-HPLC. 
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1. INTRODUCTION 
Pharmaceutical Analysis is that core branch of pharmacy education and 
research, which is advancing very fast. It can be categorized as synthesis of new 
drugs molecules and pharmaceutical analysis. Analytical chemistry is the science of 
making quantitative and qualitative measurements. In practice, quantifying an 
analyte in a complex sample becomes an exercise in problem solving. To be efficient 
and effective, an analytical chemist must know the tools that are available to tackle a 
wide variety of problems. Analytical chemistry is divided into two branches 
qualitative and quantitative. A qualitative method provides information about the 
identity of atomic or molecular species or functional groups in sample. A 
quantitative method provides numerical information as to the relative amount of one 
or more of the components1,2. Varieties of analytical methods are used for the 
analysis of drugs in bulk, formulations and biological samples. In pharmaceutical 
industry, spectrophotometric and chromatographic methods have gained the 
significance in recent years. Spectrophotometric methods3,4 It is defined as a 
method of analysis that embraces the measurement of absorption by chemical 
species of radiant energy at definite and narrow wavelength approximating 
monochromatic radiation. The electromagnetic spectrum extends from 100-780 nm. 
Traditionally, analytical chemistry has been split into two main types,( 1 ) 
Qualitative And Quantitative: Qualitative Inorganic Analysis seeks to 
establish the presence of a given element or inorganic compound in a sample. 
Qualitative Organic Analysis seeks to establish the presence of a given functional 
group or organic compound in a sample. Quantitative analysis seeks to establish the 
amount of a given element or compound in a sample.There are various techniques     
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used for analysis of mixtures. Spectroscopy measures the interaction of the 
molecules with electromagnetic radiation. Chromatography is the collective term for 
a family of laboratory techniques for the separation of mixtures. It involves passing a 
mixture dissolved in a "mobile phase" through a stationary phase, which separates 
the analyte to be measured from other molecules in the mixture and allows it to be 
isolated. Analytical Chromatography is used to determine the existence and possibly 
also the concentration of analyte(s) in a sample6. Analytical chemistry has played 
critical roles in the understanding of basic science to a variety of practical 
applications, such as biomedical applications, environmental monitoring, quality 
control of industrial manufacturing, forensic science and so on.( 2 ) 
1.1SPECTROSCOPY 
ABSORPTION SPECTROPHOTOMETRY: 
When a molecule is exposed to an electromagnetic radiation (EMR), certain 
amount of energy associated with the particular radiation is absorbed by molecule. 
As a molecule absorbs energy, an electron is promoted from an occupied orbital to 
an unoccupied orbital of greater potential energy. Generally, the most probable 
transition is from the highest occupied molecular orbital (HOMO) to the lowest 
unoccupied molecular orbital (LUMO). The energy differences between electronic 
levels in most molecules vary from 125 to 650 KJ/mole7.( 3 ) 
ULTRA VIOLET – VISIBLE SPECTROSCOPY: 
The name Ultra violet, means "beyond violet" (from Latin ultra, "beyond"), 
violet being the color of the shortest wavelengths of visible light. The color violet 
has the shortest wavelength in the visible spectrum. UV light has a shorter 
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wavelength than that of violet light. One among the various analytical techniques 
used for analysis of mixtures is spectrophotometry. It involves separation of drugs 
by physical and chemical methods and then to read them at their _max to obtain 
results. This technique involves two steps and has relatively low sensitivity. 
Derivative spectroscopy is slight advanced which do not require separation but the 
difference in _max of component of drugs need to be at least 208 nm. Amongst the 
instrumental methods Spectrophotometric occupies very important position, which 
utilizes the measurement of intensity of electromagnetic radiation, emitted or 
absorbed by the analyte. The careful manipulation of the experimental parameters in 
UV visible spectrophotometer often enables the analyte to estimate simultaneously 
more than one component present in a mixture without their prior separation. 
1.2 INTRODUCTION TO HPLC 
 The phenomenal growth in chromatography is largely due to the introduction of 
the versatile technique called high-pressure liquid chromatography, which is 
frequently called high-performance liquid chromatography. Both terms can be 
abbreviated as HPLC. 
 High-pressure liquid-solid chromatography (HPLC) is rapidly becoming the 
method of choice for separations and analysis in many fields. Almost anything 
that can be dissolved can be separated on some type of HPLC column.[8] 
Characteristics of HPLC method  
 Efficient, highly selective, widely applicable 
 Only small sample required. 
 May be nondestructive of sample 
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 Readily adapted to quantitative analysis. 
 High resolving power.( 4 ) 
Modes of HPLC:  
1. Normal phase chromatography: In normal phase mode, the nature of 
stationary phase is polar and the mobile phase is non-polar. In this technique, 
non-polar compounds travel faster and are eluted first because of the lower 
affinity between the non-polar compounds and stationary phase. Polar 
compounds are retained for longer time and take more time to elute because if 
their higher affinity with the stationary phase. Normal phase mode of separation 
is, therefore, not generally used pharmaceutical applications because most of the 
drug molecules are polar in nature and hence take longer time to elute. 
2. Reversed phase chromatography: Reversed phase mode is the most popular 
mode for analytical and preparative separations of compounds of interest in 
chemical, biological, pharmaceutical, food and biomedical sciences. In this 
mode, the stationary phase is non-polar hydrophobic packing with octyl and 
octadecyl functional group bonded to silica gel and the mobile phase is a polar 
solvent, often a partially or fully aqueous mobile phase. Polar substances prefer 
the mobile phase and elute first. As the hydrophobic character of the solutes 
increases, retention increases. Generally, the lower the polarity of the mobile 
phase, the higher is its eluent strength. The elution order of the classes of 
compounds is reversed (thus the name reverse-phase chromatography). 
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Method Devlopment on HPLC 
Method development and optimization in liquid chromatography is still an 
attractive field of research for theoreticians (researchers) and attracts also a lot of 
interest from practical analysts. Among all, the liquid chromatographic methods, the 
reversed phase systems based on modified silica offers the highest probability of 
successful results. However, a large number of (system) variables (parameters) 
affect the selectivity and the resolution. 
Alternate analytical methods are developed for the drug product to reduce 
the cost and time. When alternative analytical methods are intented to replace the 
existing procedure, analyst should collect the literature for all types of information 
related to analyte and define the separation goal. Then estimate the best separation 
condition from trial runs. After optimizing the separation condition, validate the 
method for release to routine laboratory.( 5 ) 
Getting Started on Method Development 
“Best column, best mobile phase, best detection wavelength, efforts in 
separation can make a world of difference while developing HPLC method for 
routine analysis. Determining the ideal combination of these factors assures faster 
delivery of desired results – a validated method of separation.” 
a) The Mobile Phase: In reverse-phase chromatography, the mobile phase is more 
polar than the stationary phase. Mobile phase in these systems is usually 
mixtures of two or more individual solvents with or without additives or organic 
solvent modifiers. The usual approach is to choose what appears to be the most 
appropriate column, and then to design a mobile phase that will optimize the 
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retention and selectivity of the system. Separations in these systems are 
considered to be due to different degrees of hydrophobicity of the solutes. The 
simple alteration of composition of the mobile phase or of the flow rate allows 
the rate of the elution of the solutes to be adjusted to an optimum value and 
permits the separation of a wide range of the chemical types. First isocratic run 
followed by gradient run is preferred. 
b) The Detector: The next consideration should be the choice of detector. UV-
visible detectors are the most popular as they can detect a broad range of 
compounds and have a fair degree of selectivity for some analytes. 
c) The Column Length: Many chromatographers make the mistake of simply 
using what is available. Often this is a 250 cm × 4.6 mm C18 column. These 
columns are able to resolve a wide variety of compounds. While many reverse 
phase separations can be carried out on such column. Method development can 
be streamlined by starting with shorter columns; 150, 100 or even 50 cm long. 
d) The Stationary Phase: Selecting an appropriate stationary phase can also help 
to improve the efficiency of method development. For example, a C8 phase 
(reversed phase) can provide a further time saving over a C18, as it does not 
retain analytes as strongly as the C18 phase. For normal phase applications, 
cyano (nitrile) phases are most versatile. 
e) The Internal Diameter: By selecting a shorter column with an appropriate 
phase, run times can be minimized so that an elution order and an optimum 
mobile phase can be quickly determined. 
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f) Gradient Programming: The fastest and easiest way to develop a method is to 
use a mobile phase gradient. Always start with a weak solvent strength and move 
to a higher solvent strength. To begin, use a very fast gradient (e.g.10 minutes) 
and then modify the starting and finishing mobile phases to achieve a suitable 
separation. 
g) Retention: Analytes may be too strongly retained (producing long run times). If 
this occurs, the solvent strength should be increased. In reverse phase analysis 
this means a higher % of organic solvent in the mobile phase. 
h) Poor Separation: Analytes often co-elute with each other or impurities. To 
overcome this, the analysis should be run at both higher and lower solvent 
strengths so the best separation conditions may be determined. 
i) Peak Shape: This is often a problem, especially for basic compounds analyzed 
by reversed phase HPLC. To minimize any potential problems always use a high 
purity silica phase such as Wakosil II. These modern phases are very highly 
deactivated so secondary interactions with the support are minimal. To maximize 
the reproducibility of a method, it is best to use a column heater to control the 
temperature of the separation. A temperature of 35 – 40°C is recommended. 
j) Buffer selection: In reverse phase HPLC, the retention of analytes is related to 
their hydrophobicity. The more hydrophobic the analyte, the longer it is retained. 
When an analyte is ionized, it becomes less hydrophobic and, therefore, its 
retention decreases. When separating mixtures containing acid and/or bases by 
reversed phase HPLC, it is necessary to control the pH of mobile phase using 
appropriate buffer in order to achieve reproducible results. Buffers play an 
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additional role in the reproducibility of a separation. The buffer salts reduce peak 
tailing for basic compounds by effectively masking silanols. They also reduce 
potential ion-exchange interactions with unprotonated silanols (Figure 1.2). 
 
Fig. 1.1: Peak Tailing Interaction 
k) Selection of pH: The pH range most often used for reversed-phase HPLC 
is 1 - 8 and can be divided into low pH (1 - 4) and intermediate pH (4 - 8) ranges. 
Each range has a number of advantages. Low pH has the advantage of creating an 
environment in which peak tailing is minimized and method ruggedness is, 
maximized. For this reason, operating at low pH is recommended. At a mobile phase 
pH greater than 7, dissolution of silica can severely shorten the lifetime of columns 
packed with silica-based stationary phases. 
The pKa value (acid dissociation [ionization] constant) for a compound is the 
pH at which equal concentrations of the acidic and basic forms of the molecule are 
present in aqueous solutions. Analytes may sometimes appear as broad or tailing 
peaks when the mobile phase pH is at, or near, their pKa values. A more rugged 
mobile phase pH will be at least 1 pH unit different from the analyte pKa. This shifts 
the equilibrium so that 99% of the sample will be in one form. The result is 
consistent chromatography.( 7/8 ) 
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INTRODUCTION TO METHOD VALIDATION 
“Doing thorough method validation can be tedious, but the consequences 
of not doing it right are wasted time, money, and resources.” 
Definition: Validation is a process of establishing documented evidence, 
which provides a high degree of assurance that a specific activity will consistently 
produce a desired result or product meeting its predetermined specifications and 
quality characteristics. Method validation is the process of demonstrating that 
analytical procedures are suitable for their intended use and that they support the 
identity, quality, purity, and potency of the drug substances and drug products. The 
real goal of validation process is to challenge the method and determine limits of 
allowed variability for the conditions needed to run the method.[20] 
Type of analytical procedures to be validated: Validation of analytical procedures 
is directed to the four most common types of analytical procedures. 
 Identification test. 
 Quantitative test for impurities content. 
 Limit test for the control of impurities. 
 Quantitative test of the active moiety in samples of drug substance on drug 
product on other selected components in the drug product. 
 In our method of validation, we are following last type. 
Assay procedures are intended to measure the analyst present in given 
sample, assay represent a quantitative measurement of the major component(s) in the 
drug sample. Two steps are required to evaluate an analytical method. 
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1) First determine the classification of the method. 
2) The second step is to consider the characteristics of the analytical method 
For analytical method validation of pharmaceuticals, guidelines from the 
International Conference on Harmonization (ICH), United States Food and Drug 
Administration (US FDA), American Association of Official Analytical Chemists 
(AOAC), United States Pharmacopoeia (USP) and International Union of Pure and 
Applied Chemists (IUPAC) provide a framework for performing such validations in 
efficient and productive manner. 
Reason for Method validation 
There are two important reasons for validating assays in the pharmaceutical 
industry. The first, and by for the most important, is that assay validation is an 
integral part of the quality control system. The second is that current good 
manufacturing practice regulation requires assay validation. 
Performance characteristics examined when carrying out method validation[21] 
 Specificity 
 Linearity 
 Range 
 Accuracy 
 Precision ( Repeatability and Ruggdness ) 
 Detection and Quantitation limit 
 Robustness. 
 System suitability 
The different parameters of analytical method development are discussed below as 
per ICH guideline:- 
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1) Specificity: 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include 
impurities, degradants, matrix, etc. 
An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay. The procedures 
used to demonstrate specificity will depend on the intended objective of the 
analytical procedure. 
2) Linearity: 
The linearity of an analytical procedure is its ability (within given range) to 
obtain test results, which are directly proportional to the concentration (amount) of 
analyte in the sample. 
3) Range: 
The range of analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. The specified range is normally derived from 
linearity studies and depends on the intended application of the procedure. 
4) Accuracy: 
Accuracy of analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an 
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accepted reference value and the value found. This is sometimes termed trueness. 
Accuracy should be established across the specified range of the analytical 
procedure. 
5) Precision: 
The precision of an analytical procedure expresses the closeness of 
agreement (degree of scatter) between the series of measurements obtained from 
multiple sampling of the same homogeneous sample under the prescribed conditions. 
6) Detection Limit: 
The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample, which can be detected but not necessarily quantitated 
under stated experimental conditions. 
7) Quantitation Limit: 
The quantitation limit of an individual analytical procedure is defined as the 
lowest amount of analyte in a sample, which can be quantitatively determined with 
suitable precision and accuracy. 
8) Robustness: 
The robustness of an analytical procedure is a measure of its capacity to 
remain unaffected by small, but deliberate variations in method parameters and 
provides an indication of its reliability during normal usage. 
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9) System Suitability Testing: 
The system has to be tested for its suitability for the intended purpose. 
System suitability testing is an integral part of many analytical procedures. The tests 
are based on the concept that the equipment, electronics, analytical operations and 
samples to be analyzed constitute an integral system that can be evaluated as such. 
Parameters such as plate count, tailing factors, resolution and reproducibility 
(% RSD retention time and area for six repetitions) are determined and compared 
against the specifications set for the method. 
A. Retention Time (Rt): Retention time is the time of elution of peak maximum 
after injection of compound. 
B. Theoretical Plates (N): The number of theoretical plates in column is given by 
the following relationship. 
N = 16 (t / w) 2 
Where, t is retention time and w is width at the base of the peak. 
HETP = L / N 
Where L=length of column. 
The theoretical plates should be more than 2000. 
C. Resolution(R): Resolution of two components in mixture is determined by 
following equation, 
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           2 (t2 – t1) 
R =   ------------- 
            W1+W2 
 
Where, t2 and t1 is the retention time of second and first compound 
respectively, whereas W2 and W1 are the corresponding widths at the bases of peak 
obtained by extrapolating straight sides of the peaks to baselines. 
R should be more than 2 between peaks of interest and the closest eluted 
potential interferences (impurities, excipients, degradation products or internal 
standard). 
D. Tailing Factor (T): It is the measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing become more pronounced. 
         
                         AB 
       TF  =      ---------- 
                         2AC 
            
Where, W0.05 is the width of peak at 5% height and F is the distance from 
the peak maximum to the leading edge of the peak height from baseline. 
Tailing factor should be less than 2. 
E. Capacity Factor (K’): It is calculated by using the formula, 
                
 
              t2 
K1 
  
=
    --------- 
              t1    
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Where, t is the retention time of drug and ta is the retention time of non-
retarded component, air with thermal conductivity detection. 
The following table lists the terms generally used and their recommended 
limits obtained from the analysis of the system suitability sample. 
System suitability parameters and Characteristics to be validated in HPLC 
method are given in Table 1.1 and 1.2, respectively. 
Table 1.1: System Suitability Parameters and their recommended limits. 
Parameter Recommendation 
Capacity Factor (K’) The peak should be well-resolved from other peaks and the 
Repeatability RSD ≤ 1% 
Relative Retention Not essential as the resolution is stated 
Resolution(Rs) Rs of > 2 between the peak of interest and the closest eluting 
Tailing Factor(T) T ≤ 2 
Theoretical 
Plates(N) In general should be > 2000 
 
Table 1.2: Characteristics to be validated in HPLC. 
Characteristics Acceptance Criteria 
Accuracy/trueness Recovery 98-102% (individual) 
Precision RSD < 2% 
Repeatability RSD < 2% 
Intermediate Precision RSD < 2% 
Specificity / Selectivity No interference 
Detection Limit S/N > 2 or 3 
Quantitation Limit S/N > 10 
Linearity Correlation coefficient R2 > 0.999 
Range 80 –120 % 
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2. DRUG PROFILE 
Hydrochlorothiazide, abbreviated HCTZ, HCT, or HZT, is a diuretic drug of the 
thiazide class that acts by inhibiting the kidneys' ability to retain water. This reduces the 
volume of the blood, decreasing blood return to the heart and thuscardiac output and, by 
other mechanisms, is believed to lower peripheral vascular resistance. 
 
Fig 2.1 HCTZ 
Application : A carbonic anhydrase inhibitor  
CAS Number : 58-93-5  
Purity :  ≥98%  
Molecular Weight : 297.74  
Molecular Formula : C7H8ClN3O4S2  
Physical State : Solid  
Solubility : Soluble in Methanol  
Storage : Store at room temperature  
Melting Point : 273-277°C (lit.)  
Mechanism of Action: Hydrochlorothiazide belongs to thiazide class of 
diuretics. It reduces blood volume by acting on the kidneys to reduce sodium (Na) 
reabsorption in the distal convoluted tubule. The major site of action in the nephron 
appears on an electroneutral Na+-Cl− co-transporter by competing for the chloride site on 
the transporter. 
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By impairing Na transport in the distal convoluted tubule, hydrochlorothiazide 
induces a natriuresis and concomitant water loss. Thiazides increase the reabsorption of 
calcium in this segment in a manner unrelated to sodium transport.[9] Additionally, by 
other mechanisms, HCTZ is believed to lower peripheral vascular resistance.  
Clinical pharmacology: Hydrochlorothiazide blocks the reabsorption of 
sodium and chloride ions, and it thereby increases the quantity of sodium traversing the 
distal tubule and the volume of water excreted. A portion of the additional sodium 
presented to the distal tubule is exchanged there for potassium and hydrogen ions. With 
continued use of hydrochlorothiazide and depletion of sodium, compensatory 
mechanisms tend to increase this exchange and may produce excessive loss of 
potassium, hydrogen and chloride ions. Hydrochlorothiazide also decreases the 
excretion of calcium and uric acid, may increase the excretion of iodide and may reduce 
glomerular filtration rate. Metabolic toxicities associated with excessive electrolyte 
changes caused by hydrochlorothiazide have been shown to be dose-related.  
Pharmacokinetics: Hydrochlorothiazide is well absorbed (65% to 75%) 
following oral administration. Absorption of hydrochlorothiazide is reduced in patients 
with congestive heart failure.  
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and 
range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg. Plasma 
concentrations are linearly related to the administered dose. Concentrations of 
hydrochlorothiazide are 1.6 to 1.8 times higher in whole blood than in plasma. Binding 
to serum proteins has been reported to be approximately 40% to 68%. The plasma 
elimination half-life has been reported to be 6 to 15 hours. Hydrochlorothiazide is 
eliminated primarily by renal pathways. Following oral doses of 12.5 to 100 mg, 55% to 
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77% of the administered dose appears in urine and greater than 95% of the absorbed 
dose is excreted in urine as unchanged drug. In patients with renal disease, plasma 
concentrations of hydrochlorothiazide are increased and the elimination half-life is 
prolonged.  
When HCTZ is administered with food, its bioavailability is reduced by 10%, 
the maximum plasma concentration is reduced by 20%, and the time to maximum 
concentration increases from 1.6 to 2.9 hours. 
Pharmacodynamics: Acute antihypertensive effects of thiazides are thought to 
result from a reduction in blood volume and cardiac output, secondary to a natriuretic 
effect, although a direct vasodilatory mechanism has also been proposed. With chronic 
administration, plasma volume returns toward normal, but peripheral vascular resistance 
is decreased. The exact mechanism of the antihypertensive effect of hydrochlorothiazide 
is not known.  
Thiazides do not affect normal blood pressure. Onset of action occurs within 2 
hours of dosing, peak effect is observed at about 4 hours, and activity persists for up to 
24 hours.  
Medical Uses: Hydrochlorothiazide is frequently used for the treatment of 
hypertension, congestive heart failure, symptomatic edema, diabetes insipidus, renal 
tubular acidosis, and the prevention of kidney stones.[4]  
Most of the research supporting the use of thiazide diuretics in hypertension was 
done using chlorthalidone, a different medication in the same class. Some more recent 
studies have suggested that chlorthalidone might be the more effective thiazide 
diuretic.[5]  
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It is also sometimes used for treatment of hypoparathyroidism,[6] hypercalciuria, 
Dent's disease and Ménière's disease. For diabetes insipidus, the effect of thiazide 
diuretics is presumably mediated by a hypovolemia-induced increase in proximal 
sodium and water reabsorption, thereby diminishing water delivery to the ADH-
sensitive sites in the collecting tubules and increasing the urine output.  
Thiazides are also used in the treatment of osteoporosis. Thiazides decrease 
mineral bone loss by promoting calcium retention in the kidney, and by directly 
stimulating osteoblast differentiation and bone mineral formation.[7]  
It is frequently given together with other antihypertensive agents in fixed 
combination preparations, such as losartan (anangiotensin II receptor antagonist) as 
hydrochlorothiazide/losartan.  
Adverse effects:  
• Hypokalemia, or low blood levels of potassium are an occasional side effect. It can 
be usually prevented bypotassium supplements or by combining 
hydrochlorothiazide with a potassium-sparing diuretic.  
• Other disturbances in the levels of serum electrolytes including hypomagnesemia 
(low magnesium), hyponatremia (low sodium), and hypercalcemia (high calcium).  
• Hyperuricemia, high levels of uric acid in the blood.  
• Hyperglycemia, high blood sugar.  
• Hyperlipidemia, high cholesterol and triglycerides.  
• Headache  
• Nausea/vomiting  
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• Photosensitivity  
• Weight gain  
• Gout  
• Pancreatitis. 
.  
Fig 2.2 Quinapril 
Quinapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) 
used in the treatment of hypertension and congestive heart failure. 
Application :  An angiotensin-converting enzyme (ACE) inhibitor  
CAS Number : 82586-55-8  
Purity :  ≥99%  
Molecular Weight :  474.98  
Molecular Formula :  C25H30N2O5 HCl  
Appearance :  Crystalline powder  
Physical State : Solid  
Solubility : Soluble in water (95 mg/ml at 25 °C), ethanol  
  (95 mg/ml at 25 °C), and DMSO (18 mg/ml at 25 °C).  
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Storage :  Store at room temperature  
Melting Point : 120-130 °C (lit.)  
Refractive Index : n20D 1.58 (Predicted)  
Optical Activity : α20/D +14.5º, c = 1.2 in ethanol  
IC50 :  ACE: IC50 = 8.3 nM (human); Angiotensin-converting  
  enzyme: IC50 = 4008 nM (rabbit)  
Description  
Quinapril hydrochloride (Quinapril) is an ACE angiotensin-converting 
enzyme) inhibitor with a Ki of 20 µM. Quinapril is a prodrug that is converted to its 
active metabolite, quinaprilat. Quinapril’s target, ACE, catalyses the formation of 
angiotensin II from its precursor, angiotensin I. Angiotensin II is a potent 
vasoconstrictor and thus preventing its formation causes vasodilation and an 
increased capillary blood volume.  
Mechanism of Action: Quinapril is deesterified to the principal metabolite, 
quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. 
ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the 
vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and 
incongestive heart failure (CHF) appears to result primarily from the inhibition of 
circulating and tissue ACE activity, thereby reducing angiotensin II formation. 
Quinapril inhibits the elevation in blood pressure caused by intravenously 
administered angiotensin I, but has no effect on the pressorresponse to angiotensin 
II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of 
aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid 
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reabsorption. Reduced aldosterone secretion by quinapril may result in a small 
increase in serum potassium. In controlled hypertension trials, treatment with 
Quinapril alone resulted in mean increases in potassium of 0.07 mmol/L Removal of 
angiotensin II negative feedback on renin secretion leads to increased plasma renin 
activity (PRA).   
While the principal mechanism of antihypertensive effect is thought to be 
through the reninangiotensin-aldosterone system, quinapril exerts antihypertensive 
actions even in patients with low renin hypertension. Quinapril was an effective 
antihypertensive in all races studied, although it was somewhat less effective in 
blacks (usually a predominantly low renin group) than in nonblacks. ACE is 
identical to kininase II, an enzyme that degrades bradykinin, a potent peptide 
vasodilator; whether increased levels of bradykinin play a role in the therapeutic 
effect of quinapril remains to be elucidated.  
Pharmacokinetics: Following oral administration, peak plasma quinapril 
concentrations are observed within one hour. Based on recovery of quinapril and its 
metabolites in urine, the extent of absorption is at least 60%. The rate and extent of 
quinapril absorption are diminished moderately (approximately 25–30%) when 
Quinapril tablets are administered during a high-fat meal. Following absorption, 
quinapril is deesterified to its major active metabolite, quinaprilat (about 38% of oral 
dose), and to other minor inactive metabolites. Following multiple oral dosing of 
Quinapril, there is an effective accumulation half-life of quinaprilat of 
approximately 3 hours, and peak plasma quinaprilat concentrations are observed 
approximately 2 hours post-dose. Quinaprilat is eliminated primarily by renal 
excretion, up to 96% of an IV dose, and has an elimination half-life in plasma of 
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approximately 2 hours and a prolonged terminal phase with a half-life of 25 hours. 
The pharmacokinetics of quinapril and quinaprilat are linear over a single-dose 
range of 5–80 mg doses and 40–160 mg in multiple daily doses. Approximately 
97% of either quinapril or quinaprilat circulating in plasma is bound to proteins.  
 In patients with renal insufficiency, the elimination half-life of quinaprilat 
increases as creatinine clearance decreases. There is a linear correlation between 
plasma quinaprilat clearance and creatinine clearance. In patients with end-stage 
renal disease, chronic hemodialysis or continuous ambulatoryperitoneal dialysis has 
little effect on the elimination of quinapril and quinaprilat. Elimination of quinaprilat 
may be reduced in elderly patients ( ≥ 65 years) and in those with heart failure; this 
reduction is attributable to decrease in renal function. Quinapril at concentrations are 
reduced in patients with alcoholic cirrhosisdue to impaired deesterification of 
quinapril. Studies in rats indicate that quinapril and its metabolites do not cross the 
blood-brain barrier. 
Pharmacodynamics and Clinical Effects  
Hypertension  
Single doses of 20 mg of Quinapril provide over 80% inhibition of plasma 
ACE for 24 hours. Inhibition of the pressor response to angiotensin I is shorter-
lived, with a 20 mg dose giving 75% inhibition for about 4 hours, 50% inhibition for 
about 8 hours, and 20% inhibition at 24 hours. With chronic dosing, however, there 
is substantial inhibition of angiotensin II levels at 24 hours by doses of 20–80 mg.  
Administration of 10 to 80 mg of Quinapril to patients with mild to severe 
hypertension results in a reduction of sitting and standing blood pressure to about 
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the same extent with minimal effect on heart rate. Symptomaticpostural hypotension 
is infrequent although it can occur in patients who are salt-and/or volume-depleted 
(see WARNINGS). Antihypertensive activity commences within 1 hour with peak 
effects usually achieved by 2 to 4 hours after dosing. During chronic therapy, most 
of the blood pressure lowering effect of a given dose is obtained in 1–2 weeks. In 
multiple-dose studies, 10–80 mg per day in single or divided doses lowered systolic 
and diastolic blood pressure throughout the dosing interval, with a trough effect of 
about 5–11/3–7 mm Hg. The trough effect represents about 50% of the peak effect. 
While the dose-response relationship is relatively flat, doses of 40–80 mg were 
somewhat more effective at trough than 10–20 mg, and twice daily dosing tended to 
give a somewhat lower trough blood pressure than once daily dosing with the same 
total dose. The antihypertensive effect of Quinapril continues during long-term 
therapy, with no evidence of loss of effectiveness.  
Hemodynamic assessments in patients with hypertension indicate that blood 
pressure reduction produced by quinapril is accompanied by a reduction in total 
peripheral resistance and renal vascular resistance with little or no change in heart 
rate, cardiac index, renal blood flow, glomerular filtration rate, or filtration fraction. 
Use of Quinapril with a thiazide diuretic gives a blood-pressure lowering 
effect greater than that seen with either agent alone. In patients with hypertension, 
Quinapril 10–40 mg was similar in effectiveness to captopril, enalapril, propranolol, 
and thiazide diuretics. 
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Therapeutic effects appear to be the same for elderly ( ≥ 65 years of age) and 
younger adult patients given the same daily dosages, with no increase in adverse 
events in elderly patients. 
Heart Failure 
In a placebo-controlled trial involving patients with congestive heart failure 
treated with digitalis and diuretics, parenteral quinaprilat, the active metabolite of 
quinapril, reduced pulmonary capillary wedge pressure and systemic vascular 
resistance and increased cardiac output/index. Similar favorable hemodynamic 
effects were seen with oral quinapril in baseline-controlled trials, and such effects 
appeared to be maintained during chronic oral quinapril therapy. Quinapril reduced 
renal hepatic vascular resistance and increased renal and hepatic blood flow with 
glomerular filtration rate remaining unchanged.  
A significant dose response relationship for improvement in maximal 
exercise tolerance has been observed with Quinapril therapy. Beneficial effects on 
the severity of heart failure as measured by New York Heart Association (NYHA) 
classification and Quality of Life and on symptoms of dyspnea, fatigue, and edema 
were evident after 6 months in a double-blind, placebo-controlled study. Favorable 
effects were maintained for up to two years of open label therapy. The effects of 
quinapril on long-term mortality in heart failure have not been evaluated. 
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3. LITERATURE REVIEW 
A literature survey was carried out for the simultaneous determination 
methods for the combination of HCTZ and Quinapril and references have been 
reported below: 
Altunsoy et al., (2013) reported The aim of this study was to develop a 
reversed-phase high performance liquid chromatographic (RP-HPLC) method for 
the simultaneous determination of quinapril (QNP) and hydrochlorothiazide (HCZ) 
in pharmaceutical dosage forms. In this method quinapril, hydrochlorothiazide and 
perindopril (internal standard) were separated using a reversed phase column 
(Hichrom C18; 250×4.6 mm i.d.; 10 µm) with acetonitrile: potassium dihydrogen 
phosphate (at pH 2.5; 0.067 M) (40:60 v/v) as a mobile phase. UV visible dedector 
set at 211 nm and mobile phase was pumped at 1.0 mL/min flow rate. The 
chromatographic separation was performed at 25oC. In these conditions the retention 
times for quinapril, hydrochlorothiazide and perindoprile were 4.391, 3.237 and 
3.931 min, respectively. Linearity was obtained in the concentration range of 2-30 
µg/mL for quinapril and 1.25-18.75 µg/mL for hydrochlorothiazide. The proposed 
method has been fully validated and allows a number of cost- and time-saving 
benefits. It was successfully applied to the determination of QNP and HCZ in 
synthetic mixtures and in pharmaceutical dosage forms. The proposed method is 
simple, rapid and suitable for quality control (QC) applications.( 13 ) 
Sujitha et al., (2013) reported A novel, precise, accurate, rapid and cost 
effective isocratic reverse phase high performance liquid chromatographic (RP-
HPLC) method was developed, optimized and validated for the estimation of 
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Quinapril(QPL) and Hydrochlorothiazide (HTZ) in pharmaceutical dosage forms 
(tablet). The drugs were estimated using Hypersil BDS C18 (150mm x 4.6 mm i.d- 5 
µm particle size) column. A mobile phase composed of tri ethylamine buffer, 
acetonitrile in proportion of 60:40v/v, at a flow rate of 1.0 ml/min was used 8) were 
0.0592 µg/ml and 0.1793 µg/ml for QPL and 0.0509 µg/ml 0.1543 µg/ml for HTZ 
respectively. The method was validated as per the International Conference on 
Harmonization (ICH) guidelines. The proposed validated method was successfully 
used for the quantitative analysis of commercially available dosage form.( 14 ) 
Harini et al., (2014) reported A RP–HPLC chromatographic method was 
developed and validated for the determination of Quinapril and Hydrochlorothiazide 
in bulk powder and in pharmaceutical formulations. Quinapril and 
Hydrochlorothiazide can be separated on Zorbax Eclipse XDB, C 18 column (150 x 
4.6 mm, 5 mm) at 30 °C using Acetonitrile: Phosphate buffer, pH 4.5 was adjusted 
with o-phosphoric acid in the ratio of 35:65 v/v as a mobile phase at flow rate of 
0.9mL min-1 and detected at 210 nm. The retention time of Quinapril and 
Hydrochlorthiazide was found to be 2.099min and 5.537 min respectively.( 15 ) 
The validation of the proposed method was carried out for specificity, 
linearity, accuracy, precision, LOD, LOQ and robustness. C alibration was linear 
over a range of 50-300 µg mL-1 and 31.25–187.5 µg mL-1 with correlation 
coefficient of 0.999 for Quinapril and Hydrochlorthiazide, respectively. The 
robustness of the method was evaluated by deliberately altering the chromatographic 
conditions. The method developed can be applicable for quality control analysis. 
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Rema et al., (2013) reported A new simple, sensitive, rapid, accurate, precise 
and economical RPHPLC method for the simultaneous determination of Quinapril 
HCl (QUI) and Hydrochlorthiazide (HCTZ) in their combined pharmaceutical 
dosage form was developed. In RP-HPLC analysis was carried out using potassium 
Dihydrogen Phosphate buffer (pH 4.0 adjusted with Ortho Phosphoric acid) 
:Acetonitrile(70:30v/v) mobile phase, and C18 column ODS(100 mm x 4.6 mm,3.0µ 
particle size) as stationary phase with detection wavelength of 215 nm. Linearity 
was obtained in the concentration range of 5-25 µg/ml for both the drugs. The % 
recoveries of the both the drugs were found to be 99.50 – 101.50 % and 99.00 –
101.06%respectively.The LOD were found to be 0.014µg/ml and 0.013µg/ml at 215 
nm for Quinapril Hydrochloride and Hydrochlorthiazide respectively. 
Methods were statistically validated for Accuracy, precision, specificity, 
LOQ, and robustness according to ICH guidelines and can be used for analysis of 
combined dosage form. 
Vandana et al., (2014) reported The objective of present investigation was 
to develop and validate assay methods for simultaneous estimation of quinapril 
hydrochloride and hydrochlorothiazide in combined dosage form by using three 
different analytical approaches viz. UV, FT-IR and RP-HPLC. Drugs were 
estimated by dual wavelength method and calibration curve methods by using UV 
and FT-IR spectrophotometer, respectively. The stability indicating assay method 
was developed by using HPLC. The stress degradation study was carried out 
according to International Conference on Harmonization (ICH) guideline Q1A (R2). 
Chromatographic separation was carried out on HIQ-Sil (150 × 4.6 mm, 5 µm) 
column using 0.01 M KH2PO4 buffer (pH 3.5, adjusted with orthophosphoric 
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acid): methanol as mobile phase in gradient elution mode.( 16 ) 
Arif et al., (2011) reported In the present study, a simple, sensitive and 
specific liquid chromatography (RP-HPLC) method has been developed and 
validated for the quantification of hydrochlorothiazide and losartan potassium in 
tablet dosage form. A shimpack CLC-ODS column (250 mm X 4.6 mm, 5µ and a 
mobile phase constituting 0.025 M phosphoric acid solution: acetonitrile (60:40 v/v, 
pH 3.0 adjusted with 80% phosphoric acid) were used. The flow rate was 1.5 ml/min 
and detection was carried by using ultraviolet (UV) detector at a wavelength of 254 
nm. The retention times of hydrochlorothiazide and losartan potassium were 3.748 
min and 8.790 min, respectively. 
The peaks of hydrochlorothiazide and losartan potassium were well 
separated (resolution 22.17). The calibration curves were linear over the 
concentration range of 80% to 120% (R2 > 0.999 for both the drugs). The proposed 
method is accurate with 100.165% recovery for hydrochlorothiazide and 100.422% 
recovery for losartan potassium and precise (% RSD < 0.5). The proposed method 
was successfully applied for the estimation of hydrochlorothiazide and losartan 
potassium in market products (three brands) and potency was found within limit. 
Therefore, this method can be a convenient and efficient option for the analysis of 
hydrochlorothiazide and losartan potassium in tablet dosage form.( 17 ) 
Aruna et al., (2012) reported A simple, specific, accurate and precise RP 
HPLC method has been developed for the simultaneous determination of Losartan 
Potassium (LOS) and Hydrochlorothiazide (HCTZ) from combined dosage form by 
reverse phase C18 column (Prontosil; CN (250mm x 4.6mm) 5µ). The sample was 
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analysed using Triethylamine: Acetonitrile: Methanol in the ratio of 30:30:40(pH 
adjusted to 7.0 with phosphric acid) as a mobile phase at a flow rate of 1.0ml/min 
and detection at 270nm. The retention time for Losartan potassium (LOS) and 
Hydrochlorothiazide (HCTZ) was found to be 11.869 min and 7.893 min 
respectively. The stability assay was performed for this combination and was 
validated for accuracy, precision, linearity, specificity and sensitivity in accordance 
with ICH guidelines. Validation revealed the method is specific, rapid, accurate, 
precise, reliable, and reproducible. Calibration plots were linear over the 70%-130% 
concentration ranges for both the drugs of LOS and HCTZ respectively, and 
ecoveries from combined dosage form were between 98 and 102%.( 18 ) 
Gadewar et al., (2013) reported A new, simple and sensitive reverse phase 
high performance liquid chromatographic (RP-HPLC) method has been developed 
for the separation and quantification of Hydrochlorothiazide (HCTZ) and Losartan 
Potassium (LOS) in tablet dosage form. The determination was carried out using 
GRACE C18 [4.6 x 250 mm] column as a stationary phase and mobile phase 
comprised of Acetonitrile: Phosphate Buffer (50:50) pH 3.1 in proportion of 
50:50(v/v); the pH of phosphate buffer adjusted to (3.1) using orthophosphoric acid. 
The flow rate was maintained at 1.0ml/min and the eluent was monitored at 226nm. 
The retention time of HCTZ and LOS were 4.250 min and 8.30 min respectively. 
The method was validated in terms of linearity, precision, accuracy, specificity and 
robustness. The method was linear and for precision studies; RSD for HCTZ and 
LOS were 0.02 and 0.04 respectively. The percentage recoveries for both drugs from 
their tablets were 100.80 and 99.76 respectively.( 19 ) 
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Gandhimathi et al., (2009) reported A simple, precise and rapid HPLC 
method has been developed and validated for the estimation of quinapril and 
hydrochlorothiazide simultaneously in combined dosage form. The mobile phase 
used was a mixture of 0.1% v/v triethylamine (pH 3.5), containing 1 mM of hexane 
sulphonic acid: acetonitrile (30:70% v/v). The detection of quinapril and 
hydrochlorothiazide was carried out on photo diode array detector at 220 nm. 
Results of the analysis were validated statistically and by recovery studies. The 
proposed method can be successfully used to determine the drug contents of 
marketed formulation.( 20 ) 
Girija et al., (2008) reported Quinapril hydrochloride and 
hydrochlorothiazide were simultaneously determined by HPTLC in pharmaceutical 
formulations. The drugs were separated on silica gel 60 F254 plates using suitable 
combination of solvents as mobile phase. The validation parameters, tested in 
accordance with the requirements of ICH guidelines, prove the suitability of 
methods.( 21 ) 
Reema et al., (2013) reported A new simple, sensitive, rapid, accurate, 
precise and economical Derivative Spectrophotometric method for the simultaneous 
determination of Quinapril HCl (QUI) and Hydrochlorothiazide (HCTZ) in their 
combined pharmaceutical dosage form was developed. The derivative 
Spectrophotometric method was based the absorbance of the solutions were 
measured at 242.45 nm (λ1), and 257.17 nm (λ2) for the estimation of both the 
drugs. The linearity was obtained in the concentration range of 80 - 240 µg/ml for 
QUI and 10-50µg/ml for HSCfl e mean recovery was 99.93 – 100.33 % and 99.06-
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101.25% for QUI and HCTZ respectively. The results of analysis have been 
validated statistically as per ICH guidelines.( 22 ) 
Khan et al., (2013) reported A simple, sensitive, accurate and reproducible 
method has been developed for simultaneous estimation of both the drugs by the 
Simultaneous equation method, using methanol as solvent. The two wavelengths 
257 nm λmax of Quinapril Hydrochloride (QNA-H) and 271 nm λmax of 
Hydrochlorothiazide (HCTZ) were selected for the formation of Simultaneous 
equations. The two drugs follow Beer-Lambert’s law over the concentration range 
of 5- 30 µg/ml of QNA-H and 2.5 – 15 µg/ml of HCTZ. 
Recovery study was performed to confirm the accuracy of the method. The 
recovery of the Quinapril Hydrochloride and Hydrochlorothiazide were found near 
to 100 %. The Results were found to satisfactory and reproducible. The methods 
were validated as per ICH guidelines. The proposed methods have been applied 
successfully to the analysis of cited drugs in pharmaceutical formulations.( 23 ) 
Savitha et al., (2014) reported The present study was designed with an 
objective of a simple, fast, precise, selective and accurate RP-HPLC method was 
developed and validated for the simultaneous determination of Losartan, 
Hydrochlorothiazide and Amlodipine from bulk and formulations. Reverse phase 
high performance liquid chromatography (RP-HPLC) method was developed and 
validated for rapid analysis of simultaneous determination of Losartan, 
Hydrochlorothiazide and Amlodipine. The separation of these three drugs was 
achieved on a Hypersil Gold column (250 mm X 4.6 mm, 5 µ) as stationary phase 
with a mobile phase consisting of methanol: water in the ratio of 95:5% v/v at a flow 
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rate of 0.8 mL/min and UV detection at 230 nm. The retention times were observed 
to be 2.850, 3.875 and 7.333 minutes for Losartan, Hydrochlorothiazide and 
Amlodipine, respectively. The method was statistically validated for linearity, 
recovery, limit of detection, limit of quantification, accuracy and precision. The 
method was successfully applied for analysis of combined dose tablet formulation 
containing Losartan, Hydrochlorothiazide and Amlodipine.( 24 ) 
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4. OBJECTIVE AND PLAN OF STUDY 
Literature survey reveals that, there are no simple and cost effictive  
spectrophotometric and HPLC method available for the estimation of 
“COMBINATION OF HCTZ AND Quinapril” in bulk and various pharmaceutical 
dosage forms. 
The objectives of the present work are, 
1. To develop UV-Visible spectrophotometric method for estimation of combination 
of HCTZ and Quinapril. 
2. To develop analytical method for quantitation of combination of HCTZ and 
Quinapril by RP-HPLC. 
3. Validation of all developed analytical methods as per ICH guidelines. 
4.The proposed  method  should be cost effictive  & simple method .For Analysis of 
HTCZ  and Quinapril  the  combained doses form . 
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5. MATERIALS AND METHODS 
Materials: 
HCTZ and Quinapril, Combination HCTZ and Quinapril tablets, distilled 
water, acetonitrile, phosphate buffer, ammonium acetate buffer, glacial acitic acid, 
methanol, potassium dihydrogen phosphate buffer, tetra hydrofuran, tri ethyl amine, 
orthophosphoric acid etc. 
Instrument: 
HPLC instrument used was of WATERS HPLC 2965 SYSTEM with Auto 
Injector and PDA Detector. Software used is Empower 2. UV-VIS 
spectrophotometer PG Instruments T60 with special bandwidth of 2mm and 10mm 
and matched quartz was be used for measuring absorbance for HCTZ and Quinapril 
solutions. 
Methods: 
Preparation of buffer: 
Buffer: (0.1% OPA) 
1ml of Ortho Phosphoric acid was diluted to 1000ml with HPLC grade water 
Standard Preparation: 
Accurately Weighed and transferred 10mg of Quinapril and 12.5mg of 
Hydrochlorthiazide working Standards into a 10 ml clean dry volumetric flask, add 
7ml of diluent, sonicated for 5 minutes and make up to the final volume with 
diluents. 1ml from the above two stock solutions was taken into a 10ml volumetric 
flask and made up to 10ml. 
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Sample Preparation: 
5 tablets were weighed and calculate the average weight of each tablet then 
the weight equivalent to 5 tablets was transferred into a 25 mL volumetric flask, 
20mL of diluent added and sonicated for 25 min, further the volume made up with 
diluent and filtered. From the filtered solution 0.5ml was pipeted out into a 10 ml 
volumetric flask and made upto 10ml with diluent 
Linearity: Linearity solutions are prepared such that 0.25ml, 0.5ml, 0.75ml, 
1ml, 1.25ml, 1.5ml from the Stock solutions of HCTZ and Quinapril are taken in to 
6 different volumetric flasks and diluted to 10ml with diluents to get 31.25ppm, 
62.5ppm, 93.75ppm, 125ppm, 156.25ppm, 187.5ppm of HCTZ and 25ppm, 50ppm, 
75ppm, 100ppm, 125ppm, 150ppm of Quinapril. 
Precision: 
Sample Preparation: 
5 tablets were weighed and calculate the average weight of each tablet then 
the weight equivalent to 5 tablets was transferred into a 25 mL volumetric flask, 
20mL of diluent added and sonicated for 25 min, further the volume made up with 
diluent and filtered. From the filtered solution 0.5ml was pipeted out into a 10 ml 
volumetric flask and made upto 10ml with diluent. 
Accuracy: 
50%: 5 tablets were weighed and calculate the average weight of each tablet 
then powder weight of 250mg was transferred into a 25 mL volumetric flask, 20mL 
of diluent added and sonicated for 25 min, further the volume made up with diluent 
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and filtered. From the filtered solution 0.5ml was pipeted out into a 10 ml 
volumetric flask and made up to 10ml with diluent. 
100%: 6 tablets were weighed and calculate the average weight of each 
tablet then powder weight of 500mg was transferred into a 25 mL volumetric flask, 
20mL of diluent added and sonicated for 25 min, further the volume made up with 
diluent and filtered. From the filtered solution 0.5ml was pipeted out into a 10 ml 
volumetric flask and made up to 10ml with diluent. 
150%: 10 tablets were weighed and calculate the average weight of each 
tablet then powder weight of 750mg was transferred into a 25 mL volumetric flask, 
20mL of diluent added and sonicated for 25 min, further the volume made up with 
diluent and filtered. From the filtered solution 0.5ml was pipeted out into a 10 ml 
volumetric flask and made up to 10ml with diluent. 
Method Development: 
Trial 1: This trial was run through ODS 250mm column with mobile phase 
composition of 60:40 Buffer and Acetonitrile, Flow rate set at 1ml/min. 
 
Fig 5.1 Trial chromatogram 1 
Observation : peak shape was not good and resolution is not passed 
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Trial 2: This trial was run through ODS 250mm column with mobile phase 
composition of 50:50A Buffer and Acetonitrile, Flow rate set at 1ml/min. 
 
Fig 5.2 Trial chromatogram 2 
Observation: quinapril peak shape was not good 
Trial 3: This trial was run through ODS 250mm column with mobile phase 
composition of 45:55A Buffer and Acetonitrile, Flow rate set at 1ml/min. 
 
Fig 5.3 Trial chromatogram 3 
Observation : peak shape was not good and resolution is not passed 
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Trial 4: This trial was run through BDS 250mm column with mobile phase 
composition of 40:60 Buffer, Acetonitrile and Methanol, Flow rate set at 1ml/min. 
 
Fig 5.4 Trial chromatogram 4 
Observation : peak shape was not good 
Trial 5: This trial was run through STD Altima 150mm column with mobile phase 
composition of 70:30 Buffer, Acetonitrile and Methanol, Flow rate set at 1ml/min 
 
Observation : resolution was not passed 
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Trial 6: This trial was run through STD Altima 150mm column with mobile phase 
composition of 60:40 Buffer, Acetonitrile and Methanol, Flow rate set at 1ml/min 
 
Observation : tailing is occur for quinapril  
Trial 7: This trial was run through STD Altima 150mm column with mobile phase 
composition of 55:45 Buffer, Acetonitrile and Methanol, Flow rate set at 1ml/min 
 
Observation : resolution was not passed  
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Optimized Method: Drugs were eluted with good retention time, resolution, all the 
system suitable parameters like Plate count and Tailing factor were within the limits.  
Column Used  : Innertsil ODS (250mm 4.6mm, 5µ)  
Buffer used  : Ortho phosphoric acid  
Mobile phase  : Buffer: Acetonitrile (45:55)  
Flow rate : 0.8ml/min  
Diluent : Water:Acetonitrile(50:50)  
Wavelength : 210  
Temperature  : 30oC 
Injection Volume : 10µl 
 
Fig 5.6 Optimized Chromatogram 
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6. RESULTS AND DISCUSSIONS 
1. Systemsuitability: All the system suitability parameters are within range and 
satisfactory as per ICH guidelines. 
Table: 6.1 System suitability studies of HCTZ and Quinapril 
Property HCTZ Qnlnnpi-U 
Retention time (tR) 2.174 = 03 min 3.4(57±0.3min 
Theoretical plates (N) 3162 = 163.48 5671± 1(53.48 
Tailine factor (T) 1.58 = 0.117 1.34=0.117 
 
 
Fig:6.1 Blank chromatogram 
 
Fig : 6.2 Typical chromatogram of HCTZ and Quinap ril 
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2. Linearity: Six Linear concentrations of HCTZ (31.25ppm to 187.5ppm) and 
Quinapril (25ppm to 150ppm) are prepare and Injected. Regression equation of the 
the HCTZ and Quinapril are found to be, y = 18328x + 808.5 and y = 3822.x + 
879.7 and regression co-efficient was 0.999.  
Table: 6.2 Calibration data of HCTZ and Quinapril 
S. No. Concentration Response Concentration Response 
1 0 0 0 0 
2 31.25 652346 25 461223 
3 62.5 1266327 50 908455 
4 93.75 1870418 75 1331810 
5 125 2477581 100 1783305 
6 156.25 3115270 125 2197232 
7 187.5 3800454 150 2722315 
 
 
Fig : 6.3 Calibration curve of HCTZ 
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Fig : 6.4 Calibration curve of Quinapril 
 
 
Fig: 6.5 Linearity 25% Chromatogram of HCTZ and Quinapril 
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Fig : 6.6 Linearity 50% Chromatogram of HCTZ and Quinapril  
 
 
Fig : 6.7 Linearity 75% Chromatogram of HCTZ and Quinapril 
 
 
Fig : 6.8 Linearity 100% Chromatogram of HCTZ and Quinapril 
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Fig : 6.9 Linearity 125% Chromatogram of HCTZ and Quinapril 
 
Fig : 6.10 Linearity 150% Chromatogram of HCTZ and Quinapril 
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3. Precision:  
Intraday precision (Repeatability): Intraday Precision was performed and % 
RSD for HCTZ and Quinapril were found to be 0.65% and 0.42% respectively.  
Table: 6.3 Repeatability data for HCTZ and Quinapril 
Sr. No. HC:TZ Quiuapril 
1 2427807 1826545 
2 2397565 1837939 
3 2436009 1841406 
4 2405206 1839909 
5 2415832 1847465 
Mean 2416484 1838653 
SKI Dev. 15772 7647 
%RSD 0.65 0.42 
 
 
Fig : 6.11 Repeatability Chromatogram of HCTZ and Quinapril  
Inter day precision: 
Inter day precision was performed with 24 hrs time lag and the %RSD Obtained 
for HCTZ and Quinapril were 0.23 and 0.24. 
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Table: 6.4 Inter day precision results for HCTZ and Quinapril 
Sr. No. HCTZ Quinapril 
1 2409895 1845685 
2 2437895 1833515 
3 2409312 1838087 
4 2396554 1847364 
5 2419122 1852085 
Mean 2414556 1843347 
Std. Dev. 15320 7454.71 
%RSD 0.63 0.40 
 
 
 
Fig : 6.12 Inter Day precision Chromatogram of HCTZ and Quinapril 4. Accuracy: 
Three concentrations 50%, 100%, 150%, were injected in a triplicate manner 
and amount Recovered and % Recovery were displayed in Table 6.5. 
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4. Accuracy :  
Three concentrations 50%, 100%, 150% were injected in a triplicate manner and 
amount Recovered and % Recovery were displayed in Table 6.5. 
Table: 6.5 Accuracy data of HCTZ and Quinapril 
Sample Amount 
Taken 
Amount 
Recovered 
Recovery 
(%) 
% 
RSD 
HCTZ 
62.5 62.41 99.87 0.81 
125 124.68 99.75 0.41 
1 87.5 187.81 100.17 065 
Quinapril 
50 50.13 100.27 082 
100 99 68 99.68 0 75 
150 150.31 100.21 065 
 
 
Fig : 6.13 Accuracy 50% Chromatogram of HCTZ and Quinapril 
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Fig : 6.14 Accuracy 100% Chromatogram of HCTZ and Quinapril 
 
Fig : 6.15 Accuracy 150% Chromatogram of HCTZ and Quinapril 
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5. LOD:  
Limit of ditection was calculated by intercept method and LOD for HCTZ and 
Quinapril wre found to be 0.67 and 0.5 respectively. 
 
Fig : 6.16 LOD chromatogram of HCTZ and Quinapril 
6. LOQ: Limit of Quantification was calculated by intercept method and LOQ for 
HCTZ and Quinapril were found to be 2.03 and 1.52 respectively. 
 
Fig : 6.17 LOQ chromatogram of HCTZ and Quinapril 
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7. Robustness:  
Small deliberate changes in method like Flow rate, mobile phase ratio, and 
temperature are made but there were no recognized change in the result and are within 
range as per ICH Guide lines. 
S.NO Robustness condition 
HCTZ 
%RSD 
Quinapril 
%RSD 
1 Flow minus 0.3 0.3 
2 Flow Plus 0.4 0.4 
3 Mobile phase minus 0.8 0.9 
4 Mobile phase Plus 0.7 0.9 
5 Temperature minus 0.8 0.9 
6 Temperature Plus 0.4 0.3 
 
 
6.18 Flow minus chromatogram of HCTZ and Quinapril 
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6.19 Flow plus chromatogram of HCTZ and Quinapril 
 
6.20 Mobile phase minus chromatogram of HCTZ and Quinapril 
 
6.21 Mobile phase Plus chromatogram of HCTZ and Quinapril 
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6.22 Temperature Minus chromatogram of HCTZ and Quinapril 
 
 
6.23 Temperature Plus chromatogram of HCTZ and Quinapril 
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8. Assay:  
Standard preparations are made from the API and Sample Preparations are from 
Formulation. Both sample and standards are injected six homogeneous samples. Drug in 
the formulation was estimated by taking the standard as the reference. The Average 
%Assay was calculated and found to be 99.92% and 100.02% for HCTZ and Quinapril 
respectively. 
Table 6.7 Assay of Tablet 
S. No. HCTZ %Assay Quinapril %Assay 
1 100.38 99.36 
2 99.13 99.98 
3 100.72 100.17 
4 99.44 100.09 
5 99.88 100.50 
6 99.91 100.02 
AVG 99.91 100.02 
STDEV 0.65 0.42 
%RSD 0.65 0.42 
 
 
6.24Assay of Tablet chromatogram of HCTZ and Quinapril   
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7. SUMMARY AND CONCLUSION 
Table: 7.1 Summary Table 
Parameters HCTZ Quinapril 
Calibration range 
(meg / ml) 
31.25-187.5 25- 150 
Optimized wavelength 210 210 
Mobile phase 
(Acetonitrile : Buffer) 
Buffer : Acetonitrile: 
(45:55) 
Buffer : Acetonitrile 
(45:55) 
Column Innertsil ODS (250mm 
4.6mm, 5u1 
Innertsil ODS (250mm 
4.6mm, 5n) 
Retention time 2.17 3.46 
Regression equation (Y*) y = 20044x + 4078 y=17877x + 2711 
Correlation coefficient(r~) 0.999 0.999 
Precision (% RSD*) 0.65 0.42 
% Recovery 99.91 100.02 
LOD  (mcg   ml) 0.67 0.5 
LOQ (mcg ' ml) 0.5 1.52 
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Conclusion: 
A simple, Accurate, precise method was developed for the simultaneous 
estimation of the HCTZ and Quinapril in Tablet dosage form. Retention times of 
HCTZ and Quinapril were found to be 2.17min and 3.4min. %RSD of the HCTZ 
and Quinapril were and found to be 0.65 and 0.42 respectively. %Recover was 
Obtained as 99.91 and 100.02 for HCTZ and Quinapril respectively. LOD, LOQ 
values are obtained from regression equations of HCTZ and Quinapril were 
0.67,2.03 and 0.5,1.52 respectively. Regression equation of HCTZ is y = 20044x + 
4078, and of Quinapril is y = 317877x + 2711 Regression co-efficient was 0.999. 
Retention times are decreased and that run time was decreased so the method 
developed was simple and economical that can be adopted in regular Quality control 
test in Industries.  
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